Interleukin-17A (IL-17A) is a principal driver of multiple inflammatory and immune disorders. Antibodies that neutralize IL-17A or its receptor (IL-17RA) deliver efficacy in autoimmune diseases, but no small-molecule IL-17A antagonists have yet progressed into clinical trials. Investigation of a series of linear peptide ligands to IL-17A and characterization of their binding site has enabled the design of novel macrocyclic ligands that are themselves potent IL-17A antagonists.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4985813 | PMC |
| http://dx.doi.org/10.1038/srep30859 | DOI Listing |
Publication Analysis
Top Keywords
il-17a antagonists
12
binding site
8
il-17a
6
site elucidation
4
elucidation structure
4
structure guided
4
guided design
4
design macrocyclic
4
macrocyclic il-17a
4
antagonists interleukin-17a
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!